Shots:

• Trutino to receive upfront- pre/ clinical milestones- regulatory and commercial milestones along with royalties on sales. Boehringer to get access for Trutino’s ODC platform to develop up to 3 new ODC cancer immunology candidates
• The focus of the agreement is to develop more tolerable & effective cytokine therapies for single-agent and novel combinations with Boehringer’s cancer vaccine- oncolytic virus- T cell engager- and myeloid-targeting therapies
• The collaboration will boost Boehringer’s immune-oncology portfolio by combining its breakthrough therapies with Trutino’s expertise in increasing the safety and efficacy of cytokine therapies

Click here ­to­ read full press release/ article | Ref: Boehringer Ingelheim  | Image: Boehringer Ingelheim